Drug Profile
Pembrolizumab biosimilar - Shanghai Henlius Biotech
Alternative Names: HLX-17Latest Information Update: 07 Jan 2024
Price :
$50
*
At a glance
- Originator Shanghai Henlius Biotech
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Colorectal cancer; Endometrial cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Most Recent Events
- 07 Jan 2024 Preclinical trials in Colorectal cancer in China (Parenteral) (Shanghai Henlius Biotech pipeline, December 2023)
- 07 Jan 2024 Preclinical trials in Endometrial cancer in China (Parenteral) (Shanghai Henlius Biotech pipeline, December 2023)
- 07 Jan 2024 Preclinical trials in Liver cancer in China (Parenteral) (Shanghai Henlius Biotech pipeline, December 2023)